Taisho Pharmaceutical Co., Ltd. – Product Pipeline Review – Q2 2011

Document Sample
Taisho Pharmaceutical Co., Ltd. – Product Pipeline Review – Q2 2011 Powered By Docstoc
					      Taisho Pharmaceutical Co., Ltd. – Product Pipeline
                    Review – Q2 2011
                                                                                          Reference Code: GMDHC1346CDB

                                                                                                Publication Date: JUL 2011




Taisho Pharmaceutical Co., Ltd. – Product Pipeline Review – Q2 2011                         GMDHC1346CDB / Published JUL 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                Page(1)
Taisho Pharmaceutical Co., Ltd. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                        4
List of Figures                                                                                                       4
Taisho Pharmaceutical Co., Ltd. Snapshot                                                                              5
    Taisho Pharmaceutical Co., Ltd. Overview                                                                          5
    Key Information                                                                                                   5
    Key Facts                                                                                                         5
Taisho Pharmaceutical Co., Ltd. – Research and Development Overview                                                   6
    Key Therapeutic Areas                                                                                             6
Taisho Pharmaceutical Co., Ltd. – Pipeline Review                                                                     8
    Pipeline Products by Stage of Development                                                                         8
    Pipeline Products – Monotherapy                                                                                   9
Taisho Pharmaceutical Co., Ltd. – Pipeline Products Glance                                                           10
    Taisho Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products                                                 10
         Phase II Products/Combination Treatment Modalities                                                          10
    Taisho Pharmaceutical Co., Ltd.–Early Stage Pipeline Products                                                    11
         Pre-Clinical Products/Combination Treatment Modalities                                                      11
Taisho Pharmaceutical Co., Ltd. – Drug Profiles                                                                      12
    TS-033                                                                                                           12
         Product Description                                                                                         12
         Mechanism of Action                                                                                         12
         R&D Progress                                                                                                12
    TS-071                                                                                                           13
         Product Description                                                                                         13
         Mechanism of Action                                                                                         13
         R&D Progress                                                                                                13
    TS-032                                                                                                           14
         Product Description                                                                                         14
         Mechanism of Action                                                                                         14
         R&D Progress                                                                                                14
Taisho Pharmaceutical Co., Ltd. – Pipeline Analysis                                                                  15
    Taisho Pharmaceutical Co., Ltd. – Pipeline Products by Therapeutic Class                                         15
    Taisho Pharmaceutical Co., Ltd. - Pipeline Products By Target                                                    16
    Taisho Pharmaceutical Co., Ltd. – Pipeline Products by Route of Administration                                   17
    Taisho Pharmaceutical Co., Ltd. – Pipeline Products by Molecule Type                                             18
Taisho Pharmaceutical Co., Ltd. – Recent Pipeline Updates                                                            19
Taisho Pharmaceutical Co., Ltd. - Dormant Projects                                                                   20
Taisho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products                                                     21
    Discontinued Pipeline Product Profiles                                                                           21
         TS-033                                                                                                      21
         TS022                                                                                                       21
Taisho Pharmaceutical Co., Ltd. – Company Statement                                                                  22
Taisho Pharmaceutical Co., Ltd. – Locations And Subsidiaries                                                         23
    Head Office                                                                                                      23
    Other Locations & Subsidiaries                                                                                   23
Financial Deals Landscape                                                                                            26




Taisho Pharmaceutical Co., Ltd. – Product Pipeline Review – Q2 2011                       GMDHC1346CDB / Published JUL 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(2)
Taisho Pharmaceutical Co., Ltd. – Product Pipeline Review



    Taisho Pharmaceutical Co., Ltd., Deals Volume Summary, 2004 to YTD 2011                                                      26
    Taisho Pharmaceutical Co., Ltd., Deals Summary By Region, 2004 to YTD 2011                                                   27
    Taisho Pharmaceutical Co., Ltd., Deals Summary, 2004 to YTD 2011                                                             28
    Taisho Pharmaceutical Co., Ltd. Detailed Deal Summary                                                                        30
         Asset Purchase                                                                                                          30
         Taisho Pharmaceutical Acquires OTC Drug Trademarks From Bristol-Myers Squibb                                            30
         Sanofi-aventis Acquires Ancaron Rights From Taisho Pharmaceutical                                                       32
         Acquisition                                                                                                             33
         Taisho Pharmaceutical Acquires PT Bristol-Myers Squibb Indonesia From Bristol-Myers Squibb                              33
         Taisho Pharmaceutical Acquires Minority Stake In Toyama Chemical                                                        35
         Taisho Pharmaceutical Acquires 56.93% Stake In Biofermin Pharmaceutical                                                 36
         Taisho Pharmaceutical Acquires 5.5% Stake In Yomeishu Seizo                                                             38
         Sanofi Acquires Stake In Sanofi-Synthelabo-Taisho From Taisho                                                           39
         Taisho Pharmaceutical Enters Into Agreement With Mochida Pharmaceutical                                                 40
         Taisho Pharmaceutical Enters Into Co-Development Agreement With Biofermin Pharmaceutical                                41
         Chugai Pharmaceutical Enters Into Agreement With Taisho Pharmaceutical                                                  42
         Chugai Pharmaceutical Enters Into Agreement With Taisho Pharmaceutical                                                  43
         Taisho Pharmaceutical Enters Into Agreement With TOKUHON                                                                44
         Taisho Pharmaceutical Forms Joint Venture With Toyo Shinyaku                                                            45
         Taisho Pharmaceutical Enters Into Agreement With Mikasa Seiyaku                                                         46
         Taisho Pharmaceutical Enters Into Agreement With Mikasa Seiyaku                                                         47
         Taisho Pharmaceutical Enters Into Agreement With Asubio Pharmaceuticals                                                 48
         Taisho Pharmaceutical Terminates Co-Development Agreement With Nissan Chemical                                          49
         Taisho Pharmaceutical Terminates Co-Development Agreement With Abbott Japan                                             50
         Licensing Agreements                                                                                                    51
         Taisho Pharmaceutical Enters Into Agreement With GlaxoSmithKline                                                        51
         Pfizer Enters Into Licensing Agreement With Taisho                                                                      52
         Taisho Pharmaceutical Enters Into Licensing Agreement with BrainCells                                                   53
         Bayer Schering Enters Into License Agreement With Taisho Pharmaceutical, Nihon Nohyaku And NIRS                         54
         Indigo Pharmaceuticals Enters Into Licensing Agreement With Nissan And Taisho                                           56
         Indigo Pharmaceuticals Enters Into Licensing Agreement With Nissan Chemical Industries And Taisho Pharmaceutical        57
         Nissan Chemical Industries And Taisho Pharmaceutical Enter Into Licensing Agreement With Milford Sound Sciences         58
         Eli Lilly Enters Into Licensing Agreement With Taisho Pharmaceutical                                                    59
         Taisho Pharmaceutical Terminates Licensing Agreement With Eli Lilly                                                     60
Appendix                                                                                                                         61
    Methodology                                                                                                                  61
         Coverage                                                                                                                61
         Secondary Research                                                                                                      61
         Primary Research                                                                                                        61
         Expert Panel Validation                                                                                                 62
    Contact Us                                                                                                                   62
    Disclaimer                                                  
				
DOCUMENT INFO
Description: Taisho Pharmaceutical Co., Ltd. – Product Pipeline Review – Q2 2011 Summary Global Market Direct’s pharmaceuticals report, “Taisho Pharmaceutical Co., Ltd. - Product Pipeline Review - Q2 2011” provides data on the Taisho Pharmaceutical Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Taisho Pharmaceutical Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Taisho Pharmaceutical Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Taisho Pharmaceutical Co., Ltd. - Brief Taisho Pharmaceutical Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Taisho Pharmaceutical Co., Ltd. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Taisho Pharmaceutical Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Taisho Pharmaceutical Co., Ltd.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Taisho Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Taisho Pharmaceutical Co., Ltd. in its therapy areas of focus. - Identify new drug targets and thera
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries